ArticleJournal of inflammation (London, England)2026
Bradykinin reduces wound healing in human umbilical vein endothelial cells via downregulation of vascular endothelial growth factor A.
Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHereditary angioedema (HAE) is characterized by acute swelling attacks triggered by abnormally elevated levels of bradykinin. Despite persistently high bradykinin levels, patients experience only intermittent swelling episodes. Many HAE patients, however, report triggers such as trauma preceding angioedema attacks. This suggests the involvement of additional factors, such as mechanical damage to the endothelium. Bradykinin-mediated impairment of wound healing may contribute to swelling development—a concept known as the “second hit” hypothesis. Vascular endothelial growth factors (VEGF) and their receptors play a critical role in endothelial wound healing and have also been implicated in bradykinin-mediated angioedema. This study investigates the influence of bradykinin on endothelial wound healing, with a particular focus on VEGF. MATERIALS AND
methodsHuman umbilical vein endothelial cells were incubated with bradykinin and VEGF. Gene and protein expression were analyzed by real-time polymerase chain reaction, western blotting, and immunocytochemistry. Barrier function was assessed by measuring transendothelial electrical resistance, as well as apparent and water permeability. Proliferation rates were determined using resazurin assays and real-time cell analysis. Cell migration was assessed using invasion and migration assays, and the combined effects were evaluated using scratch assays.
resultsBradykinin treatment led to reduced expression of the VEGFA isoform and its receptor VEGFR-2. VEGFA alone had no effect on bradykinin-induced barrier disruption. However, bradykinin significantly decreased endothelial proliferation and migration, resulting in impaired wound healing. This effect was counteracted by the addition of VEGFA.
conclusionsVEGFA and its receptor VEGFR-2 are key regulators of endothelial wound healing. Bradykinin impairs wound healing by reducing proliferation and migration, likely through downregulation of VEGFA and VEGFR-2. These findings support the hypothesis that bradykinin-mediated impairment of wound healing may contribute to the episodic nature of swelling attacks in patients with bradykinin-mediated angioedema, in line with the second hit hypothesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.